

Investor Briefing

Singapore & United Kingdom April 2013

Greg Kilmister - CEO



IMPORTANT NOTICE AND DISCLAIMER



- This presentation has been prepared by ALS Limited, (ALS or the Company). It contains general information about the Company's activities as at the date of the presentation. It is information given in summary form and does not purport to be complete. The distribution of this presentation in jurisdictions outside Australia may be restricted by law, and you should observe any such restrictions.
- This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy, securities in any jurisdiction. Neither this document nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate.
- The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein.
- This presentation includes forward-looking statements within the meaning of securities laws. Any forward-looking statements involve known and unknown risks and uncertainties, many of which are outside the control of the Company and its representatives. Forward-looking statements may also be based on estimates and assumptions with respect to future business decisions, which are subject to change. Any statements, assumptions, opinions or conclusions as to future matters may prove to be incorrect, and actual results, performance or achievement may vary materially from any projections and forward-looking statements.
- Due care and attention should be undertaken when considering and analysing the financial performance of the Company.
- All references to dollars are to Australian currency unless otherwise stated.

ALS Company History







Soap & Chemical Company Established

Listed on ASX

Modern Era

1863 2013





ALS Limited - Today

- Market Capitalization AUD\$3.5 billion
- Fourth largest public listed TIC company in the world
- ASX 100 participant (Sept 2011)
- Annual Revenues +AUD\$1.4 billion
- 12,000 Staff
- Operations in 56 countries on 6 continents
- Conservative Funding 28% gearing
- Commitment to technical excellence

Last Financial Release – September 2012 Half Year



half year	H1 FY12 (AUD\$m)	H2 FY12 (AUD\$m)	H1 FY13 (AUD\$m)	
Revenue	667.5	738.1	813.6	
EBITDA ¹	172.0	201.8	227.5	
EBITDA ^{1,2} from continuing operations	168.3	196.6	223.4	
Gain on sale of discontinued operations	-	-	5.8	
Impairment	-	-	(6.1)	
EBIT ¹	150.1	177.5	200.5	
NPAT	102.3	120.1	135.5	
EPS (basic - cents per share)	30.3	35.6	39.8	
Dividend (cents per share)	19	26	21	

¹ Excludes gain on sale of discontinued operations and impairment loss

² EBITDA from continuing operations post the sale of the Chemical Division (Deltrex and Panamex)


Revenue Growth




ALS (laboratories) Revenue Growth

- Organic Growth 15%
- Acquired Growth 12%
- Currency Impact 0%

Reported Growth 27%



Revenue Growth H1 2013 Vs H1 2012



ALS Divisional Structure






Industria

- Four Global Divisions
- Ten Business Streams





Revenue 2012 - AUD\$1.2 billion



Revenue 2017 - AUD\$2.0 billion

Global Diversification & Technical Leadership







>\$1.3 billion revenue

Tribology

Tribology

Tribology

Industrial

Foods
Pharmaceutical

56 countries



+20 million samples/year

>300 laboratories










9


ALS - laboratory revenue & staff distribution





Diversification & Consistent Growth






Financial Year - ending March

Revenue Growth + Margin Strength






EBITDA Margin for Core Labs, SGS, Intertek, Bureau Veritas & Eurofins is for Calendar Year 2012 actual.

EBITDA Margin & Revenue for ALS excludes non-laboratory businesses but does include all corporate expenses. Data for Financial Year ending March 2013 based on current guidance.

Operating EBITDA Margin by Division






EBITDA margins exclude ALS Limited Corporate Costs

CAPEX (excluding properties) and Depreciation






Conservative Funding



		Mar-09	Mar-10	Mar-11	Mar-12	Jan-13	
<u>Statistics</u>							
Gearing Ratio	Comfort 45%	33.7%	18.9%	11.9%	28.5%	28.8%	
Leverage (net debt / EBITDA)	Max 3.00	1.04	0.94	0.47	0.99	1.04	
EBITDA interest cover	Min 3.75	14.0	14.1	23.2	23.9	21.1	
Balance Sheet Measures							
Total Equity		413	630	826	930	1034	
Net debt		210	147	111	370	417	



- Long term Debt USPP Notes
- Bank Debt Undrawn Capacity
- Bank Debt Drawn

What makes us different



- Assets
 - State of the art laboratories
 - High end technical services
 - Unique service offerings
- Operating Model
 - Hub and spoke
 - Centres of Excellence
 - Systems and standards

"Decentralised" laboratory Vs many laboratories



- Training
- Passion
- Culture
- Loyalty
- Communication
- Strategy
 - Long-term horizon
 - Focus
 - Execution



What makes us different




- Management Information Systems (MIS)
 - LIMS
 - GEMS Geochemical
 - Coal8 Coal
 - EnviroLIMS Environmental
 - SAM Tribology
 - ELMS Food
 - OSPrey Asset Care
 - Webview Management Interface
 - WebTrieve[™]
 - Other Portals
 - iLEAD training
 - EPC succession planning
 - Compliance
 - Financial TM1
 - CAPEX
 - Safety Tracking
 - Human Resources
 - Business stream Sharepoint sites
 - Support group Sharepoint sites



World Exploration Trends (excl. iron ore & coal)







ALS Geochemistry Revenue CY2012



